MARKET

TLPH

TLPH

Talphera Inc
NASDAQ
1.230
-0.030
-2.38%
After Hours: 1.230 0 0.00% 19:59 12/05 EST
OPEN
1.260
PREV CLOSE
1.260
HIGH
1.290
LOW
1.195
VOLUME
264.25K
TURNOVER
--
52 WEEK HIGH
1.570
52 WEEK LOW
0.3800
MARKET CAP
57.33M
P/E (TTM)
-3.2540
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at TLPH last week (1124-1128)?
Weekly Report · 6d ago
Weekly Report: what happened at TLPH last week (1117-1121)?
Weekly Report · 11/24 09:06
Weekly Report: what happened at TLPH last week (1110-1114)?
Weekly Report · 11/17 09:06
Maxim Group Remains a Buy on Talphera (TLPH)
TipRanks · 11/14 14:55
Analysts Conflicted on These Healthcare Names: Talphera (TLPH) and Bausch + Lomb Corporation (BLCO)
TipRanks · 11/14 12:30
Talphera, Inc. Earnings Call: Balancing Achievements and Challenges
TipRanks · 11/14 00:19
Talphera Reports Q3 2025 Financial Results and Updates
TipRanks · 11/13 04:09
Talphera signals study completion in first half of 2026 as new site activations delay NEPHRO timeline
Seeking Alpha · 11/13 00:12
More
About TLPH
Talphera, Inc. is a specialty pharmaceutical company focused on the development and commercialization of therapies for use in medically supervised settings. The Company’s portfolio consists of nafamostat product candidates and pre-filled syringe product candidates. The Company’s lead product candidate, Niyad, is a lyophilized formulation of nafamostat and is being studied under an investigational device exemption (IDE) as an anticoagulant for the extracorporeal circuit. Niyad is used in adult patients undergoing continuous renal replacement therapy (CRRT). LTX-608 is its nafamostat formulation for direct IV infusion being explored as an investigational product for one or more indications, including antiviral treatment, or treatment of acute respiratory distress syndrome (ARDS) disseminated intravascular coagulation (DIC), or acute pancreatitis. The Company’s two ready-to-use pre-filled syringe (PFS) product candidates include Fedsyra and phenylephrine.

Webull offers Talphera Inc stock information, including NASDAQ: TLPH real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, TLPH stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading TLPH stock methods without spending real money on the virtual paper trading platform.